As a recipient of the European Commission “Seal of Excellence” for their SME grant, MultiplexDX was selected among 25 other EU participants to join the InvestHorizon Accelerator Programme, which took place in Paris, France from June 3rd to 7th, 2019. The accelerator programme, financed by the European Commission, in association with EUREKA, was implemented by a consortium coordinated by Tech Tour. It included coaching, thematic boot camps, workshops and pitching events, with the goal of bringing together EU investors with promising SMEs that are preparing to cross the “second equity gap”. This year, investors paid attention to deep tech startups focusing on biotech, digital health, medtech and diagnostics.
Our company was represented by Dr. Peter Kilian, COO of MultiplexDX.
“It is a great opportunity for MultiplexDX to be part of this programme, because it is designed for companies looking for series A funding. The challenging programme offered three days of bootcamp, collaborative forums and pitching academy. The feedback for MultiplexDX exceeded our expectations and we showed professionality and investment readiness.”
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected Europe’s ambitious high-tech companies. The programme fast tracks the fundraising efforts and helps startups boost their investment readiness and investor relations. The idea of InvestHorizon Accelerator is supported and financed by the European Commission and Eureka. The mission of this programme is to help selected applicants of SME grants to access finance and scale-up their companies.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.